0001572426-17-000020.txt : 20170802
0001572426-17-000020.hdr.sgml : 20170802
20170802212241
ACCESSION NUMBER: 0001572426-17-000020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170731
FILED AS OF DATE: 20170802
DATE AS OF CHANGE: 20170802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Farrell Geraldine T
CENTRAL INDEX KEY: 0001632385
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36828
FILM NUMBER: 171001899
MAIL ADDRESS:
STREET 1: C/O NEXVET BIOPHARMA PLC
STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK
STATE: L2
ZIP: 00000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nexvet Biopharma plc
CENTRAL INDEX KEY: 0001618561
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
BUSINESS PHONE: 353 1 215 8100
MAIL ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
FORMER COMPANY:
FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd
DATE OF NAME CHANGE: 20140903
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2017-07-31
1
0001618561
Nexvet Biopharma plc
NVET
0001632385
Farrell Geraldine T
C/O NEXVET BIOPHARMA PLC
UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD
TULLAMORE
L2
R35 FR98
IRELAND
0
1
0
0
VP Operations, General Counsel
Ordinary Shares
2017-07-31
4
D
0
18980
6.72
D
0
D
Ordinary Shares
2017-07-31
4
D
0
33180
6.72
D
0
I
Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Family A/C>
Restricted Share Units
.125
2017-07-31
4
D
0
30000
6.595
D
2017-07-01
2021-07-01
Ordinary Shares
30000
0
D
Restricted Share Units
.125
2017-07-01
4
D
0
4678
6.595
D
2020-07-01
Ordinary Shares
4678
0
D
Option to Purchase Shares
15.00
2017-07-31
4
D
0
20000
0
D
2020-05-18
Ordinary Shares
20000
0
D
Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer (the "Acquisition")
The reporting person and her spouse have shared voting and dispositive power with respect to these reported securities.
This restricted share unit, which would have vested and become convertible as to 10,000 shares on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $197,850. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit.
This restricted share unit, which would have vested and become convertible as to 2,339 shares on each of 7/1/18 and 7/1/19, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $30,851.41. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit.
This option, which was vested as to 14,000 shares and would have vested as to 1,000 shares on each of 9/30/17, 12/31/17, 3/31/18, 6/30/18, 9/30/18 and 12/31/18, was cancelled in the Acquisition in exchange for no cash payment because the $15.00 exercise price per share exceeded the $6.72 consideration per share payable in connection with in the Acquisition.
/s/ Geraldine T. Farrell
2017-07-31